Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
Status:
Unknown status
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects
with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Phase:
Phase 3
Details
Lead Sponsor:
Beijing Continent Pharmaceutical Co, Ltd.
Collaborators:
GNI-EPS Pharmaceuticals, Inc. (GNI Group) Shanghai Genomics, Inc.